This guideline introduces the management and treatment of glucocorticoid-induced osteoporosis.
Glucocorticoid-induced osteoporosis (GIO) is a major side effect of long-term corticosteroid therapy, affecting 30-50% of patients and leading to fractures. The guidelines emphasize the importance of early prevention of bone density loss and reduction of fracture risk immediately after starting glucocorticoid treatment.
The 2014 update was developed based on new evidence, including domestic cohort analyses to identify fracture risk factors specific to Japan, and the exclusion of the FRAX tool for GIO due to its limitations in predicting morphometric vertebral fractures. The guidelines aim to provide a practical system for evaluating fracture risk and determining drug therapy initiation thresholds. This manual is written in Japanese.
It is osteoporosis that occurs as a side effect of glucocorticoid treatment.
Reports say 30-50% of patients receiving long-term steroid treatment have fractures.
They are outside FRAX's target population.
Bisphosphonate treatment lowers fracture risk by 52.8%.